Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1005–1011. doi: 10.1038/sj.bjc.6690161

Inactivation of the transforming growth factor β type II receptor in human small cell lung cancer cell lines

S Hougaard 1, P Nørgaard 1, N Abrahamsen 1, H L Moses 3, M Spang-Thomsen 2, H Skovgaard Poulsen 1
PMCID: PMC2362261  PMID: 10098728

Abstract

Transforming growth factor β (TGF-β) exerts a growth inhibitory effect on many cell types through binding to two types of receptors, the type I and II receptors. Resistance to TGF-β due to lack of type II receptor (RII) has been described in some cancer types including small cell lung cancer (SCLC). The purpose of this study was to examine the cause of absent RII expression in SCLC cell lines. Northern blot analysis showed that RII RNA expression was very weak in 16 of 21 cell lines. To investigate if the absence of RII transcript was due to mutations, we screened the poly-A tract for mutations, but no mutations were detected. Additional screening for mutations of the RII gene revealed a GG to TT base substitution in one cell line, which did not express RII. This mutation generates a stop codon resulting in predicted synthesis of a truncated RII of 219 amino acids. The nature of the mutation, which has not previously been observed in RII, has been linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. Since RII has been mapped to chromosome 3p22 and nearby loci are often hypermethylated in SCLC, it was examined whether the lack of RII expression was due to hypermethylation. Southern blot analysis of the RII promoter did not show altered methylation patterns. The restriction endonuclease pattern of the RII gene was altered in two SCLC cell lines when digested with Sma 1. However, treatment with 5-aza-2′-deoxycytidine did not induce expression of RII mRNA. Our results indicate that in SCLC lack of RII mRNA is not commonly due to mutations and inactivation of RII transcription was not due to hypermethylation of the RII promoter or gene. Thus, these data show that in most cases of the SCLC cell lines, the RII gene and promoter is intact in spite of absent RII expression. However, the nature of the mutation found could suggest that it was caused by cigarette smoking. © 1999 Cancer Research Campaign

Keywords: small cell lung cancer, cell lines, transforming growth factor β, type II receptor, mutation, transcription

Full Text

The Full Text of this article is available as a PDF (468.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berendsen H. H., de Leij L., de Vries E. G., Mesander G., Mulder N. H., de Jong B., Buys C. H., Postmus P. E., Poppema S., Sluiter H. J. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res. 1988 Dec 1;48(23):6891–6899. [PubMed] [Google Scholar]
  2. Cui W., Fowlis D. J., Bryson S., Duffie E., Ireland H., Balmain A., Akhurst R. J. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 1996 Aug 23;86(4):531–542. doi: 10.1016/s0092-8674(00)80127-0. [DOI] [PubMed] [Google Scholar]
  3. Cui W., Kemp C. J., Duffie E., Balmain A., Akhurst R. J. Lack of transforming growth factor-beta 1 expression in benign skin tumors of p53null mice is prognostic for a high risk of malignant conversion. Cancer Res. 1994 Nov 15;54(22):5831–5836. [PubMed] [Google Scholar]
  4. Damstrup L., Rygaard K., Spang-Thomsen M., Skovgaard Poulsen H. Expression of transforming growth factor beta (TGF beta) receptors and expression of TGF beta 1, TGF beta 2 and TGF beta 3 in human small cell lung cancer cell lines. Br J Cancer. 1993 May;67(5):1015–1021. doi: 10.1038/bjc.1993.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Denissenko M. F., Pao A., Tang M., Pfeifer G. P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 1996 Oct 18;274(5286):430–432. doi: 10.1126/science.274.5286.430. [DOI] [PubMed] [Google Scholar]
  6. Ferguson A. T., Lapidus R. G., Baylin S. B., Davidson N. E. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. Cancer Res. 1995 Jun 1;55(11):2279–2283. [PubMed] [Google Scholar]
  7. Garrigue-Antar L., Muñoz-Antonia T., Antonia S. J., Gesmonde J., Vellucci V. F., Reiss M. Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells. Cancer Res. 1995 Sep 15;55(18):3982–3987. [PubMed] [Google Scholar]
  8. Geiser A. G., Burmester J. K., Webbink R., Roberts A. B., Sporn M. B. Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J Biol Chem. 1992 Feb 5;267(4):2588–2593. [PubMed] [Google Scholar]
  9. Gonzalez-Zulueta M., Bender C. M., Yang A. S., Nguyen T., Beart R. W., Van Tornout J. M., Jones P. A. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 1995 Oct 15;55(20):4531–4535. [PubMed] [Google Scholar]
  10. Graff J. R., Herman J. G., Lapidus R. G., Chopra H., Xu R., Jarrard D. F., Isaacs W. B., Pitha P. M., Davidson N. E., Baylin S. B. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 1995 Nov 15;55(22):5195–5199. [PubMed] [Google Scholar]
  11. Inagaki M., Moustakas A., Lin H. Y., Lodish H. F., Carr B. I. Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5359–5363. doi: 10.1073/pnas.90.11.5359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kingsley D. M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms. Genes Dev. 1994 Jan;8(2):133–146. doi: 10.1101/gad.8.2.133. [DOI] [PubMed] [Google Scholar]
  13. Liabakk N. B., Talbot I., Smith R. A., Wilkinson K., Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996 Jan 1;56(1):190–196. [PubMed] [Google Scholar]
  14. Lin H. Y., Wang X. F., Ng-Eaton E., Weinberg R. A., Lodish H. F. Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell. 1992 Feb 21;68(4):775–785. doi: 10.1016/0092-8674(92)90152-3. [DOI] [PubMed] [Google Scholar]
  15. Lu S. L., Akiyama Y., Nagasaki H., Saitoh K., Yuasa Y. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun. 1995 Nov 13;216(2):452–457. doi: 10.1006/bbrc.1995.2644. [DOI] [PubMed] [Google Scholar]
  16. Lu S. L., Zhang W. C., Akiyama Y., Nomizu T., Yuasa Y. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res. 1996 Oct 15;56(20):4595–4598. [PubMed] [Google Scholar]
  17. Makos M., Nelkin B. D., Lerman M. I., Latif F., Zbar B., Baylin S. B. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1929–1933. doi: 10.1073/pnas.89.5.1929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R. S., Zborowska E., Kinzler K. W., Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995 Jun 2;268(5215):1336–1338. doi: 10.1126/science.7761852. [DOI] [PubMed] [Google Scholar]
  19. Mitsudomi T., Oyama T., Nishida K., Ogami A., Osaki T., Sugio K., Yasumoto K., Sugimachi K., Gazdar A. F. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res. 1996 Jul;2(7):1185–1189. [PubMed] [Google Scholar]
  20. Moses H. L. TGF-beta regulation of epithelial cell proliferation. Mol Reprod Dev. 1992 Jun;32(2):179–184. doi: 10.1002/mrd.1080320215. [DOI] [PubMed] [Google Scholar]
  21. Myeroff L. L., Parsons R., Kim S. J., Hedrick L., Cho K. R., Orth K., Mathis M., Kinzler K. W., Lutterbaugh J., Park K. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res. 1995 Dec 1;55(23):5545–5547. [PubMed] [Google Scholar]
  22. Nørgaard P., Damstrup L., Rygaard K., Spang-Thomsen M., Skovgaard Poulsen H. Growth suppression by transforming growth factor beta 1 of human small-cell lung cancer cell lines is associated with expression of the type II receptor. Br J Cancer. 1994 May;69(5):802–808. doi: 10.1038/bjc.1994.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nørgaard P., Hougaard S., Poulsen H. S., Spang-Thomsen M. Transforming growth factor beta and cancer. Cancer Treat Rev. 1995 Jul;21(4):367–403. doi: 10.1016/0305-7372(95)90038-1. [DOI] [PubMed] [Google Scholar]
  24. Nørgaard P., Spang-Thomsen M., Poulsen H. S. Expression and autoregulation of transforming growth factor beta receptor mRNA in small-cell lung cancer cell lines. Br J Cancer. 1996 May;73(9):1037–1043. doi: 10.1038/bjc.1996.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Park K., Kim S. J., Bang Y. J., Park J. G., Kim N. K., Roberts A. B., Sporn M. B. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8772–8776. doi: 10.1073/pnas.91.19.8772. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pettengill O. S., Sorenson G. D., Wurster-Hill D. H., Curphey T. J., Noll W. W., Cate C. C., Maurer L. H. Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung. Cancer. 1980 Mar 1;45(5):906–918. doi: 10.1002/1097-0142(19800301)45:5<906::aid-cncr2820450513>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  27. Pierce D. F., Jr, Gorska A. E., Chytil A., Meise K. S., Page D. L., Coffey R. J., Jr, Moses H. L. Mammary tumor suppression by transforming growth factor beta 1 transgene expression. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4254–4258. doi: 10.1073/pnas.92.10.4254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Takenoshita S., Hagiwara K., Gemma A., Nagashima M., Ryberg D., Lindstedt B. A., Bennett W. P., Haugen A., Harris C. C. Absence of mutations in the transforming growth factor-beta type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles. Carcinogenesis. 1997 Jul;18(7):1427–1429. doi: 10.1093/carcin/18.7.1427. [DOI] [PubMed] [Google Scholar]
  29. Tani M., Takenoshita S., Kohno T., Hagiwara K., Nagamachi Y., Harris C. C., Yokota J. Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. Carcinogenesis. 1997 May;18(5):1119–1121. doi: 10.1093/carcin/18.5.1119. [DOI] [PubMed] [Google Scholar]
  30. Todd S., Franklin W. A., Varella-Garcia M., Kennedy T., Hilliker C. E., Jr, Hahner L., Anderson M., Wiest J. S., Drabkin H. A., Gemmill R. M. Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res. 1997 Apr 1;57(7):1344–1352. [PubMed] [Google Scholar]
  31. Vincent F., Nagashima M., Takenoshita S., Khan M. A., Gemma A., Hagiwara K., Bennett W. P. Mutation analysis of the transforming growth factor-beta type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-beta. Oncogene. 1997 Jul 3;15(1):117–122. doi: 10.1038/sj.onc.1201166. [DOI] [PubMed] [Google Scholar]
  32. de Leij L., Postmus P. E., Buys C. H., Elema J. D., Ramaekers F., Poppema S., Brouwer M., van der Veen A. Y., Mesander G., The T. H. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res. 1985 Dec;45(12 Pt 1):6024–6033. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES